

Relevant recent publications, Department of Health Economics, Corvinus University

Baji P, Gulácsi L, Lovász BD, Golovics PA., Brodszky V, Péntek M, Rencz F, Lakatos P. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. *Scandinavian Journal of Gastroenterology*. 2016 Jan;51(1):22-7. (Epub: 2015 June 10). IF: 2.361

Brodszky V, Rencz F, Péntek , Baji P, Lakatos PL, Gulácsi L. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. *Expert Rev Pharmacoecon Outcomes Res*. Epub: 2015 Jul 10:1-7. IF: 1.669.

Gulácsi L, Brodszky V, Baji P, HoUng Kim, Su Yeon Kim, Yu Young Cho, PéntekM. Biosimilars for the management of rheumatoid arthritis: economic considerations. *Expert Rev. Clin. Immunol*. 2015 Sep;11 Suppl 1:43-52. IF: 2.484

Péntek M, Poór G, Wiland P, Olejárová M, Brzosko M, Codreanu C, Brodszky N, Gulácsi L. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. *Eur J Health Econ*. 2014 May;15 Suppl 1:S35-43. IF: 1.774

Gulácsi, L., Rencz, F., Péntek, M., Brodszky, V., Lopert, R., Hever, N. V., Baji, P. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. *Eur J Health Econ*. 2014, 15 Suppl 1, S27-34. IF: 1.774

Gulácsi, L., Rotar, A. M., Niewada, M., Loblova, O., Rencz, F., Petrova, G., Boncz, I., Klazinga, N. S. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. *Eur J Health Econ*. 2014, 15 Suppl 1, 13-25. IF: 1.913

Baji P, Gulácsi L, Golovics PA., Lovász BD, Péntek M, Brodszky V, Rencz F, Lakatos P. Perceived risks contra benefits of using biosimilar drugs in ulcerative colitis; discrete choice experiment among gastroenterologists. Submitted to: *Digestive and Liver disease* (IF: 2.963), 2015. October

Baji, P., Péntek, M., Czirják, L., Szeé8kanecz, Z., Nagy, G., Gulácsi, L., Brodszky, V. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. *Eur J Health Econ*. 2014, 15 Suppl 1, 53-64. IF: 1.774

Brodszky V, Baji P, Balogh O, Pentek M: Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. *Eur J Health Econ* .2014, 15 Suppl 1, 65-71. IF: 1.774

Baji, P., Péntek, M., Szanto, S., Geher, P., Gulácsi, L., Balogh, O., Brodszky, V. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. *Eur J Health Econ*. 2014, 15 Suppl 1, 45-52. IF: 1.774